Skip to main content
. Author manuscript; available in PMC: 2015 Dec 30.
Published in final edited form as: J Neurooncol. 2015 Jun 13;124(2):307–316. doi: 10.1007/s11060-015-1841-y

Fig. 1.

Fig. 1

Effects of treatment and lymphocyte reinfusion on CD4+ and CD8+ cells. a Absolute CD4+ cell counts from week 0 to 6 while patients were treated with concurrent RT/TMZ; b absolute CD4+ cell counts from week 6 to 20 after lymphocyte reinfusion; c normalized CD4+ cell counts from week 0 to 20 during the study period (normalized to baseline), plotted individually for each patient in the study; d absolute CD8+ cell counts from week 0 to 6 while patients were treated with concurrent RT/TMZ; e absolute CD8+ cell counts from week 6 to 20 after lymphocyte reinfusion; f normalized CD8+ cell counts from week 0 to 20 during the study period (normalized to baseline), plotted individually for each patient in the study; g ratio of CD4+/CD8+ overtime in the patients who underwent lymphocyte harvest and reinfusion asterisk denotes p value < 0.05. Double asterisks denotes p value < 0.01